# A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

> **NCT07483632** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Biogen** · enrollment: 185 (estimated)

## Conditions studied

- Relapsing Forms of Multiple Sclerosis

## Interventions

- **DRUG:** Diroximel Fumarate
- **DRUG:** Dimethyl Fumarate
- **DRUG:** Fingolimod
- **DRUG:** Placebo matching DRF
- **DRUG:** Placebo matching DMF
- **DRUG:** Placebo matching fingolimod

## Key facts

- **NCT ID:** NCT07483632
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-16
- **Primary completion:** 2034-07-28
- **Final completion:** 2035-06-19
- **Target enrollment:** 185 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483632, "A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07483632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*